Nanoparticles that release a drug only when exposed to near-infrared (NIR) light are a promising drug-delivery agent developed by Canadian researchers.
Use of a nanoparticle to deliver drugs may reduce tumors and suppress metastatic escape. These efforts offer a way to control drug release over space and time while reducing systemic drug exposure and the associated side effects.
Exosome serves as a natural nanoparticle delivery system and achieves the same cancer-killing effect on drug-resistant lung cancer as current formulations of drug therapy with 50x less drug.
A new analysis of a phase III trial of patients with neuroendocrine tumors that began in the gastrointestinal (GI) tract or at an unknown primary location found that progression-free survival was improved with everolimus by 6 to 8 months compared with placebo.
A drug currently approved for GI conditions may prevent the development of colorectal cancer, according to researchers who revealed a biological connection between obesity and increased risk for colorectal cancer.
Patients with breast cancer whose health insurance plans included prescription drug benefits were 10% more likely to start important hormonal therapy than patients who did not have prescription drug coverage.
Women who have ovarian cancer often develop ascites, a buildup of fluids in the abdomen. Researchers have found that ascites can be reduced with minimal side effects through inhibition of the colony-stimulating-factor-1 receptor (CSF1R).
Researchers announced a breakthrough advance in a world-first international clinical trial of a new drug to treat chronic lymphocytic leukemia and non-Hodgkin lymphoma that is refractory or resistant to current chemotherapies.
Recent laboratory findings provide novel insight into potential new therapeutic approaches for triple-negative breast cancer, a particularly difficult-to-treat and aggressive form of the disease.
Atezolizumab may substantially change treatment strategies for patients with refractory lung cancer, according the first efficacy results from the POPLAR and BIRCH studies, which studied the PD-L1 antibody across treatment lines.
Current results from a clinical trial comparing a combination of two targeted therapies with a single-agent treatment for advanced melanoma has shown patients are living significantly longer with the combination therapy.
Brentuximab vedotin is proven an effective and safe first course of treatment for older patients with Hodgkin lymphoma who are not candidates for chemotherapy.
Researchers are working on a way to use artificial intelligence to predict a patient's response to two common chemotherapy drugs used to treat breast cancer: paclitaxel and gemcitabine.
Researchers have shown that a certain protein becomes overabundant in pancreatic neuroendocrine tumors, allowing them to thrive. They also found that pairing a synthetic compound with an existing drug provides a more effective anticancer punch than a single drug.
Comparison of cardiac events associated with liposomal doxorubicin, epirubicin and doxorubicin in breast cancer: a Bayesian network meta-analysis - European Journal of CancerSeptember 04, 2015
A recent study examined the cardiotoxicity of anthracyclines in patients with breast cancer.
Researchers have pinpointed a novel genetic biomarker responsible for the progression of many breast and prostate cancers.
Ion channel blockers, drugs commonly used to treat cardiac, neurologic, and psychiatric disorders, might prove useful in cancer therapy, according to new research.
By surrounding molecules of paclitaxel with self-assembling spheres composed of amino acids, researchers doubled tumor exposure to the drug and reduced its effects on healthy tissue.
An increasing number of oncology/hematology treatments will consist of oral oncolytics, and oncology programs are needed to manage the treatment of patients following these regimens.
The discovery of an enzyme that facilitates the spread of breast cancer may enable clinicians to prevent secondary cancer.
A combination approach utilizing three differing anticancer drug classes could hold the key to besting glioblastoma.
Drugs that are more commonly used to treat melanoma can also be use to help some individuals with lung cancer, research indicates.
Peripheral neuropathy associated with nab-paclitaxel among chemotherapy-naïve patients can be managed by dose interruptions and modifications.
A phase 3 trial of brentuximab vedotin (BV) showed that adults with hard-to-treat Hodgkin lymphoma given BV after stem cell transplantation survived without the disease progression for twice as long as when a placebo was administered.
Acute lymphoblastic leukemia (ALL) has been found to have two distinct subtypes, and evidence indicates that roughly 13% of ALL cases may be successfully treated with targeted drugs used in the treatment of lymphomas in adults.
Low doses of metformin and a gene inhibitor known as BI2536 can successfully halt the growth of late-stage prostate cancer tumors.
According to a new study, patients with diabetes become less adherent to their diabetes medication regimen following a diagnosis of cancer.
In treatment for metastatic breast cancer, eribulin is effective as a first-, second-, or third-line chemotherapy regimen.
How should a fibrin overgrowth on an internal catheter be managed when there is no blood return from the implanted port?
A drug used to treat Lou Gehrig's disease has also been found to improve the effectiveness of radiation therapy when administered to laboratory models with melanoma that metastasized to the brain.
- Prostate-Specific Antigen (PSA) Test (Fact Sheet)
- Inconclusive: The Pulmonary Nodules You Need to Follow
- Proposed Regimen for Ovarian Cancer Is Aggressive, But Could Achieve a 50% Cure Rate
- Better Approaches to Patient Counseling of BRCA Gene Mutation Carriers Needed
- Dasatinib, Nilotinib, Ponatinib Increase Vascular Occlusive Events
- Low-income Breast Cancer Survivors Benefit From Personalized Survivorship Care Plans
- Understanding Drug Naming Nomenclature
- Nurse Navigators Key to Seamless Transition From Pediatric to Adult Survivorship Care
- Common Painkiller Has Anticancer Effects
- Palliative Care is Cost Effective for Cancer Patients, and Increases With Comorbidities
- Cola Consumption May Increase Erlotinib Absorption in Patients Taking PPIs
- Nab-paclitaxel Increases Complete Response Rate in Invasive Breast Cancer
- Understanding Participation Factors Related to Web- and Phone-based Tobacco Cessation Programs
- Satisfaction With Navigators Associated With Satisfaction With Cancer-related Care
- Earlier and More Frequent Tanning Bed Use by Women Associated With Melanoma Incidence and Age at Diagnosis
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|